Approval · Notice of Compliance 5187 · 1995
NAPROSYN: Notice of Compliance 5187
Issued June 5, 1995
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5187
- Date
- June 5, 1995
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Anti-inflammatory agent with analgesic and antipyretic properties
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAPROSYN | 02162474 | Cancelled Post Market |
| NAPROSYN | 02162482 | Cancelled Post Market |
| NAPROSYN | 02162490 | Cancelled Post Market |
| NAPROSYN | 02162792 | Cancelled Post Market |
| NAPROSYN | 02162415 | Cancelled Post Market |
| NAPROSYN | 02162423 | Marketed |
| NAPROSYN | 02162466 | Marketed |
| NAPROSYN | 02162431 | Marketed |
| NAPROSYN | 02162458 | Cancelled Post Market |
| NAPROSYN | 02168871 | — |